Sanofi's multiple sclerosis drug, rejected by the FDA, received a positive review from European regulators recommending its approval. This divergence highlights the varying regulatory standards and outcomes between the U.S. and Europe, offering developers insights into tailoring their approval strategies across different markets. Developers should watch for potential shifts in how drugs are evaluated and approved globally.
Read the full article at STAT News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
2
alinemati1983-6987Written by alinemati1983-6987
